Bevacizumab beyond disease progression for advanced non–small cell lung cancer: Does persistence have its rewards?

Persistence pays off when it comes to the vascular endothelial growth factor inhibitor bevacizumab in non–small cell lung cancer patients who have progressed on first‐line chemotherapy. Continued vascular endothelial growth factor blockade after progression on first‐line therapy may provide at least...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Vol. 122; no. 7; pp. 1047 - 1049
Main Authors: Guijarro‐Muñoz, Irene, Roarty, Emily B., Heymach, John V.
Format: Journal Article
Language:English
Published: United States 01-04-2016
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first